REG - Life Science REIT - Result of AGM

Life Science ReitAnnouncement

23/05/2024 17:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240523:nRSW7294Pa&default-theme=true

RNS Number : 7294P  Life Science REIT PLC  23 May 2024

Life Science REIT plc

(the "Company")

 

LEI: 213800RG7JNX7K8F7525

 

23 May 2024

 

Annual General Meeting ("AGM") Results

The Company announces that at its Annual General Meeting held earlier today
all the resolutions set out in the Notice of Annual General Meeting were
passed. All resolutions were voted on by way of a poll.  The results of the
poll for each resolution were as follows:

 

                                                                                  For                     Against

 Resolution                                                                                                                      Votes Withheld

                                                                                                                                 (No. of shares)

                                                                                  No. of shares           No. of shares  %

                                                                                                 %

                                                                                  247,928,546    99.99%   14,663         0.01%   26,709

 1.   To receive and approve the annual report and financial statements

 2.   To receive and approve the Directors' remuneration report                   247,684,045    99.97%   68,743         0.03%   217,130

 3.   To approve the Company's dividend payment policy                                           99.99%   3,000          0.01%   0

                                                                                  247,966,918

 4.   To re-elect Claire Boyle as a Director of the Company                                      95.31%   11,291,786     4.69%   7,431,487

                                                                                  229,246,645

 5.   To re-elect Sally Ann Forsyth as a Director of the Company                                 94.13%   13,561,582     5.87%   16,953,402

                                                                                  217,454,934

 6.   To re-elect Michael Taylor as a Director of the Company                                    99.18%   1,963,083      0.82%   7,431,487

                                                                                  238,575,348

 7.   To re-elect Richard Howell as a Director of the Company                                    99.18%   1,965,648      0.82%   7,431,487

                                                                                  238,572,783

                                                                                  247,897,047    99.97%   64,398         0.03%   8,473

 8.   To re-appoint Deloitte LLP as Auditor to the Company

                                                                                                 99.98%   53,346         0.02%   0

 9.   To authorise the Audit and Risk Committee to determine the remuneration     247,916,572
 of the Auditor to the Company

 10.  To authorise the Directors to allot equity securities                                      89.84%   25,192,883     10.16%  0

                                                                                  222,777,035

                                                                                  232,274,638    93.68%   15,668,571     6.32%   26,709

 11.  To authorise the Directors to disapply pre-emption rights*

                                                                                  231,970,086    93.58%   15,920,407     6.42%   79,425

 12.  To authorise the Directors to disapply pre-emption rights for the
 purposes of financing an acquisition or other capital investment*

                                                                                                          11,635,663     4.69%   0

 13.  To approve the purchase of the Company's own shares*

                                                                                  236,334,255    95.31%

 14.  That a general meeting, other than an AGM, may be called on not less        244,386,609    98.56%   3,580,744      1.44%   2,565
 than 14 clear days' notice*

 

*special resolution

 

 NOTES:

 1.      All resolutions were passed.

 2.      Percentages have been rounded to two decimal places.

 3.      Proxy appointments which gave discretion to the Chair of the AGM have been
         included in the "For" total for the appropriate resolution.

 4.      Votes "For" and "Against" any resolution are expressed as a percentage of
         votes validly cast for that resolution.

 5.      A "Vote withheld" is not a vote in law and is not counted in the calculation
         of the percentage of shares voted "For" or "Against" any resolution.

 6.      The number of shares in issue at 6:00 pm. on 21 May 2024 was 350,000,000
         ordinary shares, carrying one vote each, and at that time, the Company did not
         hold any shares in treasury.

 7.      The full text of the resolutions passed at the AGM can be found in the Notice
         of Annual General Meeting which is available on the Company's website at
         https://lifesciencereit.co.uk/investors/shareholder-information/
         (https://lifesciencereit.co.uk/investors/shareholder-information/)

 

Enquiries:

 Link Company Matters Limited - Company Secretary
 labs_cosec@linkgroup.co.uk

 Ironstone Asset Management - Investment Adviser
 Simon Farnsworth/ Joanna Waddingham                            via Buchanan below

 Panmure Gordon - Joint Corporate Broker                        +44 20 7886 2500
 Alex Collins / Tom Scrivens

 Jefferies International Limited - Joint Corporate Broker       +44 20 7029 8000
 Tom Yeadon

 G10 Capital Limited - AIFM                                     +44 20 7397 5450
 Verity Morgan-Jones / Maria Baldwin

 Buchanan - Financial PR                                        +44 20 7466 5000
 Mark Court / Henry Wilson / Verity Parker
 LifeSciencereit@buchanan.uk.com

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGAJMATMTATBPI